Supplementary Data 1 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial

L. Collet; Maude Ardin; David Venet; Justine Berthet; Sarah Barrin; Isabelle Treilleux; Jean‐Christophe Noël; Marianne Leheurteur; Jérôme Meunier; Leïla Bengrine-Lefèvre; Mathilde Martinez; Frank Priou; Frédèric Selle; Pierre-Alexandre Just; Guillaume Bataillon; Françoise Rothé; Christos Sotiriou; Christophe Caux; Bertrand Dubois; Isabelle Ray‐Coquard; Olivia Le Saux

doi:10.1158/1078-0432.29760223

Key Points

MAIN FINDING: Differential expression of genes was identified between pd-l1 positive and negative high-grade serous ovarian cancer samples.
KEY EVIDENCE: Gene set enrichment analyses highlighted significant differences between tumor types within the neopebrov cohort.
APPROACH: The analysis compared gene expression profiles from primary tumors and metastases to understand the tumor microenvironment.
SIGNIFICANCE: Findings may help in developing targeted therapies for patients with high-grade serous ovarian cancer.

Implication

Phase II trial reveals differences in pd-l1 expression and gene profiles between ovarian cancer types, indicating novel therapeutic targets.

Abstract

Supplementary Data 1. Differentially expressed genes and Gene Set Enrichment Analyses between PD-L1 positive and negative samples and between tubo-ovarian primary and metastases in the NeoPembrOv cohort.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Collet et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d0255 https://doi.org/10.1158/1078-0432.29760223

View Full Paper

Ask AI

Bookmark

Share

Supplementary Data 1 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Data 1 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading